¼¼°èÀÇ Àü¸³¼± ºñ´ëÁõ Ä¡·á±â ½ÃÀå
Benign Prostatic Hyperplasia Devices
»óǰÄÚµå : 1559694
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 192 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,104,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,312,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Àü¸³¼± ºñ´ëÁõ Ä¡·á±â ¼¼°è ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 8¾ï 1,650¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î Àü¸Á

2023³â 5¾ï 8,280¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â Àü¸³¼± ºñ´ëÁõ Ä¡·á±â ¼¼°è ½ÃÀåÀº 2030³â¿¡´Â 8¾ï 1,650¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2023-2030³â µ¿¾È 4.9%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ º´¿ø ÃÖÁ¾ ¿ëµµ ºÎ¹®Àº CAGR 5.3%¸¦ ±â·ÏÇÏ¿© ºÐ¼® ±â°£ÀÌ ³¡³¯ ¶§±îÁö 4¾ï 9,690¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ºñ´¢±â°ú Ŭ¸®´Ð ÃÖÁ¾ ¿ëµµ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 4.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ¾à 1¾ï 5,850¸¸ ´Þ·¯, Áß±¹Àº CAGR 4.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î Àü¸Á

¹Ì±¹ÀÇ Àü¸³¼± ºñ´ëÁõ Ä¡·á±â ½ÃÀåÀº 2023³â 1¾ï 5,850¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö ½ÃÀå ±Ô¸ð°¡ 1¾ï 2,950¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023-2030³â ºÐ¼® ±â°£ µ¿¾È 4.7%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ µ¿¾È °¢°¢ 4.7%¿Í 4.1%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ 4.9%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àü ¼¼°è Àü¸³¼±ºñ´ëÁõ Ä¡·áÁ¦ ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

Çö´ë Ä¡·á¿¡¼­ Àü¸³¼± ºñ´ëÁõ Ä¡·á±âÀÇ ¿ªÇÒÀº ¹«¾ùÀΰ¡?

Àü¸³¼± ºñ´ëÁõ(BPH) Ä¡·á±â´Â Àü¸³¼± ºñ´ëÁõ °ü¸®¿¡ ÇʼöÀûÀÎ µµ±¸·Î, °í·É ³²¼º¿¡°Ô ÈçÇÑ Àü¸³¼± ºñ´ëÁõ°ú °ü·ÃµÈ Áõ»ó°ú ÇÕº´ÁõÀ» Å©°Ô ÁÙÀÏ ¼ö ÀÖ´Â ÃÖ¼Òħ½ÀÀû ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Àåºñ´Â ±âÁ¸ÀÇ ¼ö¼úÀû Á¢±Ù¹ýÀ» ´ëüÇÏ´Â °ÍÀ¸·Î, º¸´Ù Ç¥ÀûÈ­µÈ ȯÀÚ Ä£È­ÀûÀÎ Ä¡·á¸¦ °¡´ÉÇÏ°Ô Çϸç, °æ¿äµµÀû Àü¸³¼± ÀýÁ¦¼ú(TURP) Àåºñ, ·¹ÀÌÀú Ä¡·á ½Ã½ºÅÛ, Àü¸³¼± ½ºÅÙÆ®, ¼öÁõ±â ¿ä¹ý ¹× Àü¸³¼± ¿äµµ ¸®ÇÁÆ®(PUL) ½Ã½ºÅÛ°ú °°Àº »õ·Î¿î Ä¡·á¹ýÀ» Æ÷ÇÔÇÕ´Ï´Ù. Ä¡·á¹ý µî ´Ù¾çÇÑ ±â¼úÀÌ Æ÷ÇԵ˴ϴÙ. ¿äµµ¸¦ ¸·°í ÀÖ´Â °úµµÇÑ Àü¸³¼± Á¶Á÷À» Á¦°ÅÇϰųª Àç¹èÄ¡ÇÏ¿© ¼Òº¯ÀÇ È帧À» °³¼±ÇÏ°í ºó´¢ ¹× ¿äÆó¿Í °°Àº °ü·Ã Áõ»óÀ» ¿ÏÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ã·´Ü ±â±âÀÇ µµÀÔÀ¸·Î ³²¼ºµéÀº ¼±ÅÃÀÇ ÆøÀÌ ³Ð¾îÁ³À¸¸ç, ƯÁ¤ °Ç°­ ¿ä±¸¿Í ȸº¹ ¸ñÇ¥¿¡ µû¶ó º¸´Ù ¸ÂÃãÈ­µÈ Ä¡·á Àü·«À» ¼ö¸³ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

±â¼ú Çõ½ÅÀº ¾î¶»°Ô BPH Ä¡·á±âÀÇ È¿°ú¸¦ Çâ»ó½Ã۴°¡?

±â¼ú Çõ½ÅÀº BPH Ä¡·á±âÀÇ È¿°ú¿Í ¾ÈÀü¼ºÀ» Å©°Ô Çâ»ó½ÃÄÑ È¯ÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí Ä¡·á ¼±ÅÃÀÇ ÆøÀ» ³ÐÇû½À´Ï´Ù. Ȧ¹Å ·¹ÀÌÀú Àü¸³¼± ÀýÁ¦¼ú(HoLEP)°ú °°Àº ·¹ÀÌÀú Ä¡·á ½Ã½ºÅÛÀº Á¤¹ÐÇÑ ·¹ÀÌÀú ±â¼úÀ» Ȱ¿ëÇÏ¿© ÃÖ¼ÒÇÑÀÇ Ä§½ÀÀ¸·Î °úµµÇÑ Á¶Á÷À» Á¦°ÅÇÔÀ¸·Î½á ±âÁ¸ÀÇ ¼ö¼úÀû ¹æ¹ý¿¡ ¼ö¹ÝµÇ´Â À§ÇèÀ» ÁÙ¿´½À´Ï´Ù. ¼öÁõ±â¸¦ ÀÌ¿ëÇØ Àü¸³¼± Á¶Á÷À» Ãà¼ÒÇÏ´Â ¼öÁõ±â Ä¡·á¿Í °°Àº Çõ½ÅÀûÀÎ Ä¡·á¹ýÀº ºñħ½ÀÀûÀ̰í Àå±âÀûÀ¸·Î ¿ì¼öÇÑ °á°ú¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ Àü¸³¼± ¿äµµ ¸®ÇÁÆ®(PUL) ½Ã½ºÅÛÀÇ °³¹ßÀº Àü¸³¼± Á¶Á÷À» ÀÚ¸£°Å³ª Á¦°ÅÇÏÁö ¾Ê°í ¹°¸®ÀûÀ¸·Î Àç¹èÄ¡ÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀ» Á¦°øÇÔÀ¸·Î½á Àü¸³¼± ºñ´ëÁõ Ä¡·á¿¡ Çõ¸íÀ» ÀÏÀ¸ÄÑ ¼º±â´ÉÀ» À¯ÁöÇÏ°í ´õ ºü¸¥ ȸº¹À» º¸ÀåÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº Àü¸³¼±ºñ´ëÁõ Ä¡·áÀÇ ¼º°ø·üÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó, º¸´Ù Ä£¼÷Çϰí ȯÀÚµéÀÇ »î¿¡ ´õ ÀûÀº ÁöÀåÀ» ÃÊ·¡ÇÏ¿© ´õ ¸¹Àº ³²¼ºµéÀÌ ÀÌ·¯ÇÑ Çõ½ÅÀûÀÎ ÇØ°áÃ¥À» ãµµ·Ï À¯µµÇϰí ÀÖ½À´Ï´Ù.

º¸°ÇÀÇ·á ½Ã½ºÅÛ Àüü¿¡¼­ BPH Ä¡·á±â¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

BPH Ä¡·á±â¿¡ ´ëÇÑ ¼ö¿ä´Â ¸î °¡Áö Áß¿äÇÑ Ãß¼¼·Î ÀÎÇØ ÀÇ·á ½Ã½ºÅÛ Àü¹Ý¿¡¼­ ºü¸£°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è ³ëÀÎ Àα¸ÀÇ Áõ°¡·Î ÀÎÇØ BPH ¹ßº´·üÀÌ ³ô¾ÆÁö¸é¼­ È¿°úÀûÀ̰í ÃÖ¼Òħ½ÀÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿À´Ã³¯ ȯÀÚµéÀº ´õ ¸¹Àº Á¤º¸¸¦ °®°í ÀÖ°í, ȸº¹ ½Ã°£ÀÌ Âª°í À§ÇèÀÌ ÀûÀº ¿Ü·¡ ¼ö¼úÀ» ¼±È£ÇÏ´Â °æ¿ì°¡ ¸¹±â ¶§¹®¿¡ BPH Ä¡·á±â´Â ƯÈ÷ ¸Å·ÂÀûÀ̸ç, BPH Áõ»ó¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÷´Ü Ä¡·á ¿É¼ÇÀ» ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÊ¿¡ µû¶ó ´õ ¸¹Àº ³²¼ºÀÌ Á¶±â¿¡ Àǻ縦 ¸¸³ª°Ô µÇ¾î BPH Ä¡·á±â¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. BPH Ä¡·á±â¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºñ¿ë Àý°¨°ú ȯÀÚ °á°ú °³¼±¿¡ ÃÊÁ¡À» ¸ÂÃá °¡Ä¡ ±â¹Ý ÀÇ·á ¸ðµ¨·ÎÀÇ ÀüȯÀº ÀÇ·á ¼­ºñ½º Á¦°øÀÚµéÀÌ °íǰÁúÀÇ È¿À²ÀûÀÎ Ä¡·á¸¦ Á¦°øÇÒ ¼ö ÀÖ´Â BPH Ä¡·á ±â±â¸¦ µµÀÔÇϵµ·Ï À¯µµÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº Çö´ë ºñ´¢±â°ú ÀÇ·á¿¡ ÇʼöÀûÀÎ Á¸Àç°¡ µÇ°í ÀÖ´Â BPH ±â±âÀÇ »ç¿ë È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

BPH Àåºñ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?

BPH Ä¡·á ±â±â ½ÃÀåÀÇ ¼ºÀåÀº °í·ÉÈ­ »çȸ¿¡¼­ÀÇ BPH À¯º´·ü Áõ°¡¿Í Ä¡·á¸¦ ÇÊ¿ä·Î Çϴ ȯÀÚÃþÀÇ È®´ë µî ¿©·¯ ¿äÀο¡ ±âÀÎÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á ±â¼úÀÇ ¹ßÀü, ƯÈ÷ ·¹ÀÌÀú Ä¡·á¿Í Àü¸³¼± ¿äµµ ¸®ÇÁÆ® ½Ã½ºÅÛ°ú °°Àº ´ú ħ½ÀÀûÀÎ ½Ã¼úÀÇ °³¹ßÀº º¸´Ù ¾ÈÀüÇϰí È¿°úÀûÀÎ Ä¡·á ¿É¼ÇÀ» Á¦°øÇÔÀ¸·Î½á ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÔ¿ø ±â°£°ú ÀÇ·áºñ¸¦ Àý°¨ÇÒ ¼ö ÀÖ´Â ¿Ü·¡ Ä¡·á¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼­ ÀÌ·¯ÇÑ ÀåºñÀÇ Ã¤ÅÃÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, BPH¿Í »îÀÇ Áú¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Á¶±â °³ÀÔÀ» ¿øÇÏ´Â ³²¼ºÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Çõ½ÅÀûÀÎ BPH Ä¡·á ±â±â¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼ÀÇ Áö¼ÓÀûÀÎ ¹ßÀü°ú ÇÔ²² BPH ±â±â ½ÃÀåÀº Áö¼ÓÀûÀÎ ±â¼ú Çõ½Å°ú È¿°úÀûÀ̰í ȯÀÚ Ä£È­ÀûÀÎ Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ÈûÀÔ¾î °­·ÂÇÑ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê(38°³»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Benign Prostatic Hyperplasia Devices Market to Reach US$816.5 Million by 2030

The global market for Benign Prostatic Hyperplasia Devices estimated at US$582.8 Million in the year 2023, is expected to reach US$816.5 Million by 2030, growing at a CAGR of 4.9% over the analysis period 2023-2030. Hospitals End-Use, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$496.9 Million by the end of the analysis period. Growth in the Urology Clinics End-Use segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$158.5 Million While China is Forecast to Grow at 4.7% CAGR

The Benign Prostatic Hyperplasia Devices market in the U.S. is estimated at US$158.5 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$129.5 Million by the year 2030 trailing a CAGR of 4.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.7% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Benign Prostatic Hyperplasia Devices Market - Key Trends and Drivers Summarized

What Role Do Benign Prostatic Hyperplasia Devices Play in Modern Treatment?

Benign Prostatic Hyperplasia (BPH) devices are essential tools in the management of prostate enlargement, offering minimally invasive solutions that significantly reduce the symptoms and complications associated with this common condition in aging men. These devices provide alternatives to traditional surgical approaches, enabling more targeted and patient-friendly treatments. BPH devices include a range of technologies such as transurethral resection of the prostate (TURP) instruments, laser therapy systems, prostatic stents, and newer treatments like water vapor therapy and prostatic urethral lift (PUL) systems. By either removing or repositioning excess prostate tissue that blocks the urethra, these devices improve urinary flow and alleviate related symptoms like frequent urination and urinary retention. The introduction of these advanced devices has expanded the options available to men, allowing for more personalized treatment strategies that align with their specific health needs and recovery goals.

How Are Technological Innovations Enhancing BPH Device Effectiveness?

Technological innovations have significantly enhanced the effectiveness and safety of BPH devices, leading to better patient outcomes and broader treatment options. Laser therapy systems, such as holmium laser enucleation of the prostate (HoLEP), leverage precision laser technology to remove excess tissue with minimal invasiveness, reducing the risks associated with traditional surgical methods. Innovations like water vapor therapy, which utilizes steam to shrink prostate tissue, offer a non-invasive alternative with excellent long-term results. Additionally, the development of prostatic urethral lift (PUL) systems has revolutionized BPH treatment by providing a method to physically reposition the prostate tissue without cutting or removing it, thus preserving sexual function and ensuring quicker recovery. These advancements are not only improving the success rates of BPH treatments but also making them more accessible and less disruptive to patients' lives, encouraging more men to seek out these innovative solutions.

Why Is There Increasing Demand for BPH Devices Across Healthcare Systems?

The demand for BPH devices is rapidly increasing across healthcare systems due to several key trends. The growing elderly population worldwide is leading to a higher incidence of BPH, creating a greater need for effective, minimally invasive treatment options. Patients today are more informed and often prefer outpatient procedures that offer shorter recovery times and lower risks, which makes BPH devices particularly appealing. Increased awareness about BPH symptoms and the availability of advanced treatment options are prompting more men to seek medical attention earlier, thereby boosting the demand for these devices. Additionally, the shift towards value-based healthcare models, which focus on improving patient outcomes while reducing costs, is driving healthcare providers to adopt BPH devices that can deliver high-quality, efficient care. These factors are contributing to the growing utilization of BPH devices, which are becoming an integral part of modern urological care.

What Are the Key Factors Driving the Growth of the BPH Devices Market?

The growth in the BPH devices market is driven by several factors, including the rising prevalence of BPH among the aging population, which is expanding the pool of patients requiring treatment. Advances in medical technology, particularly in the development of less invasive procedures such as laser therapies and prostatic urethral lift systems, are also fueling market growth by offering safer, more effective treatment options. The increasing preference for outpatient care, which reduces hospitalization time and healthcare costs, is further boosting the adoption of these devices. Additionally, heightened awareness of BPH and its impact on quality of life is leading more men to seek early intervention, thus driving demand for innovative BPH devices. As these trends continue to evolve, the BPH devices market is expected to experience robust growth, supported by ongoing technological innovations and the rising demand for effective, patient-friendly treatment solutions.

Select Competitors (Total 38 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â